Does autologous fibrin sealant (vivostat©) reduce the incidence of postoperative pancreatic fistula after distal pancreatectomy? – a matched pairs analysis. Issue 1 (2nd January 2021)

• Record Type: Journal Article
• Authors: Luu, Andreas Minh; Braumann, Chris; Uhl, Waldemar; Janot-Matuschek, Monika; Herzog, Torsten
• Is Part Of: Acta chirurgica belgica. Volume 121:Issue 1(2021)
• Page Start: 16
• Page End: 22
• Publication Date: 2021-01-02
• Subjects: Distal pancreatectomy -- postoperative pancreatic fistula -- autologous fibrin sealant (Vivostat©) -- pancreatic surgery; Surgery -- Periodicals; General Surgery; Chirurgie -- Périodiques; Surgery; Chirurgie (geneeskunde); Periodicals; Periodicals; 617.005
• DOI: 10.1080/00015458.2019.1658354
• Languages: English
• ISSNs: 0001-5458

Abstract

Abstract: Background: Postoperative pancreatic fistula (POPF) is the most common complication following distal pancreatectomy. This retrospective study investigated the effects of autologous fibrin sealant (Vivostat © ) in reducing the incidence of POPF after distal pancreatectomy. Methods: A matched pairs analysis was performed to compare the incidence of clinically relevant POPF of 41 patients who underwent a distal pancreatectomy with application of autologous fibrin sealant (Vivostat © ) with a historical control group. Results: Clinically relevant POPF were present in 11 patients in the study group (27%) and in 13 patients in the control group (32%, p = .639). No patient of the study group required emergency angiographic treatment for postoperative hemorrhage due to POPF, whereas three patients were identified in the control group (7%, p = .079). Conclusions: POPF cannot be prevented under treatment with autologous fibrin sealant (Vivostat © ). We observed the tendency of a lower rate of postoperative pancreatic hemorrhage due to POPF. However, prospective randomized controlled studies are required.